Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  European Journal of Cancer

• Publication date

  1998-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0959-8049(98)00009-4PMID 9849494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.

  1994cited by this paper
• Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors.

  1994cited by this paper
• Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.

  1993cited by this paper
• Review article: 5‐hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications

  1992cited by this paper
• Ondansetron in carcinoid syndrome.

  1992cited by this paper
• Ondansetron in carcinoid syndrome.

  1992cited by this paper
• Therapy for symptoms in the carcinoid syndrome.

  1989cited by this paper
• Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects.

  1988cited by this paper
• Applied potential tomography. A new noninvasive technique for measuring gastric emptying.

  1987cited by this paper
• Carcinoid tumors and syndrome.

  1987cited by this paper
• Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist.

  1987cited by this paper
• On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy.

  1983cited by this paper

• What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators

  2023cites this paper
• Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome

  2022cites this paper
• Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management

  2021cites this paper
• Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms

  2020cites this paper
• CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome

  2020cites this paper
• Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome

  2020cites this paper
• The safety of lanreotide for neuroendocrine tumor

  2019cites this paper
• Management of carcinoid syndrome: a systematic review and meta-analysis.

  2019cites this paper
• Nutritional and vitamin status in patients with neuroendocrine neoplasms

  2019cites this paper
• Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.

  2019cites this paper
• Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

  2019cites this paper
• CMAR_A_181439 7537..7556

  2019cites this paper
• Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

  2018cites this paper
• New Treatments for the Carcinoid Syndrome.

  2018cites this paper
• Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.

  2018cites this paper
• Pancreatic neuroendocrine tumors: contemporary diagnosis and management

  2016cites this paper
• Carcinoid Heart Disease: A Review

  2016cites this paper
• Management of the hormonal syndrome of neuroendocrine tumors

  2016cites this paper
• MEDICAL TREATMENT OF NEUROENDOCRINE TUMORS (NETs) OF THE LUNG

  2015cites this paper
• Approach to the patient with diarrhea

  2015cites this paper
• Neuroendocrine Tumors of the Pancreas

  2015cites this paper
• Acute Endocrine and Metabolic Emergencies in Neuroendocrine Tumors

  2014cites this paper
• Clinical Approaches of Emergencies in Neuroendocrine Tumors

  2014cites this paper
• Ondansetron for diarrhea associated with neuroendocrine tumors.

  2013cites this paper
• CHAPTER 44 – Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), Carcinoid Syndrome, and Related Disorders

  2011cites this paper
• Management of Neuroendocrine Tumor Hormonal Syndromes

  2011cites this paper
• Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Thorax ( Includes Lung and Thymus )

  2010cites this paper
• Fibrosis and carcinoid syndrome: from causation to future therapy

  2009cites this paper
• Síndrome carcinoide (SC)

  2008cites this paper
• Effects of Ondansetron on Gastric Tone and Motility Changes Induced by a Prolonged Intraduodenal Infusion of Nutrients. Results of a Placebo-Controlled Study

  2007cites this paper
• Carcinoid Syndrome (CS)

  2007cites this paper
• Therapeutic options for gastrointestinal carcinoids.

  2006cites this paper
• Review article: pathogenesis and management of gastric carcinoid tumours

  2006cites this paper
• Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).

  2005cites this paper
• Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).

  2005cites this paper
• Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.

  2004cites this paper
• Complications of Midgut Carcinoid Tumors and Carcinoid Syndrome

  2004cites this paper
• The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice.

  2002cites this paper